Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Deals Drug

Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury

Fineline Cube Oct 23, 2024

Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the...

Policy / Regulatory

Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines

Fineline Cube Oct 23, 2024

The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP)...

Company Drug

Walvax Biotechnology’s Weuphoria Vaccine Approved in Oman for Pediatric Pneumococcal Infections

Fineline Cube Oct 23, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that it has...

Company Medical Device

German Endoscope Maker KARL STORZ Secures Marketing Approval for Disposable Ureteroscope in China

Fineline Cube Oct 23, 2024

KARL STORZ SE & Co. KG, a leading German endoscope manufacturer, has announced that it...

Company Drug

LENZ Therapeutics’ Presbyopia Therapy LNZ100 Accepted for FDA Review

Fineline Cube Oct 23, 2024

LENZ Therapeutics, Inc. (NASDAQ: LENZ), a US-based biopharmaceutical company, has announced that the US Food...

Company

Macrolux Raises Over RMB 100 Million in Series B Financing

Fineline Cube Oct 23, 2024

Macrolux, a leading medical technology company specializing in disposable endoscopes, has announced the completion of...

Company Drug

AstraZeneca’s Wainzua Earns CHMP Nod for hATTR-PN Treatment in the EU

Fineline Cube Oct 22, 2024

UK pharmaceutical juggernaut AstraZeneca (AZ, NASDAQ: AZN) has announced that Wainzua (eplontersen), an RNA-targeted therapy...

Company Drug

Novo Nordisk’s Semaglutide Shows 14% Reduction in Cardiovascular Events in Landmark SOUL Trial

Fineline Cube Oct 22, 2024

Copenhagen-based healthcare giant Novo Nordisk (NYSE: NVO) has declared the primary outcomes of the SOUL...

Company Medical Device

Thermo Fisher’s Oncomine Dx Target Test Gets FDA Green Light as Companion Diagnostic for Servier’s Voranigo

Fineline Cube Oct 22, 2024

US pharmaceutical and biotechnology company Thermo Fisher Scientific (NYSE: TMO) has received marketing approval from...

Company Deals

GSK and Cambridge University Forge £50 Million Partnership to Tackle Immune Diseases

Fineline Cube Oct 22, 2024

UK pharmaceutical giant GSK plc (LON: GSK, NYSE: GSK) has unveiled a significant five-year partnership...

Company Drug

AstraZeneca’s Saphnelo Approved for Use in Guangdong Under ‘Hong Kong-Macau Drug Access’ Policy

Fineline Cube Oct 22, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that its drug Saphnelo...

Company Deals

InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal

Fineline Cube Oct 22, 2024

InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement...

Company Drug

BeiGene’s Tevimbra Receives CHMP Recommendation for Expanded Use in G/GEJ and ESCC Cancers in EU

Fineline Cube Oct 22, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has received...

Company Drug

Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine

Fineline Cube Oct 22, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, has announced that...

Drug Medical Device Policy / Regulatory

Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies

Fineline Cube Oct 22, 2024

The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative...

Company Drug

Sino Biopharmaceutical’s Anlotinib Receives Ninth Indication Approval from China’s CDE for Soft-Tissue Sarcoma

Fineline Cube Oct 22, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company in China, has announced that it...

Company

GenScript Dissolves Merger with CAR-T Specialist Legend Biotech, Reclassifies as Associated Company

Fineline Cube Oct 22, 2024

GenScript Biotech Corporation (HKG: 1548), a comprehensive life science research and application service and product...

Policy / Regulatory

China’s NMPA Greenlights Pilot Plan for Phased Manufacturing of Biological Products

Fineline Cube Oct 22, 2024

The National Medical Products Administration (NMPA) has given its stamp of approval to the “Pilot...

Company Deals

Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific

Fineline Cube Oct 22, 2024

Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of...

Company Deals Medical Device

Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection

Fineline Cube Oct 22, 2024

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire...

Posts pagination

1 … 333 334 335 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.